NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
VERAXA Biotech Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
VERAXA Biotech has initiated cell line development for its lead BiTAC(R) T-cell engager program in partnership with ATUM, marking a key milestone toward IND/CTA-enabling studies. The collaboration supports manufacturing and nonclinical studies, advancing the company's oncology pipeline.
It is VERAXA's most advanced oncology candidate, a T-cell engager designed to improve selectivity and reduce toxicity compared to conventional approaches.
VERAXA selected ATUM to generate stable clonal cell lines using ATUM's Leap-In Transposase(R) technology to support manufacturing development for its lead candidate.
It represents a critical development milestone that supports manufacturing, analytical development, and nonclinical studies required before clinical testing.
The BiTAC(R) platform is designed to improve selectivity, potentially reducing the toxicity associated with conventional T-cell engager approaches.
VERAXA recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.
The candidate will advance toward IND/CTA-enabling studies, which include nonclinical studies required before clinical testing in humans.
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA's lead therapeutic candidate.